Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference

Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria

Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates

Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

Synlogic Joins Russell 3000® Index

Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update

Synlogic Announces Leadership Change

Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria

Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria